3.74
0.08 (2.19%)
| Previous Close | 3.66 |
| Open | 3.61 |
| Volume | 4,008,000 |
| Avg. Volume (3M) | 3,937,262 |
| Market Cap | 2,723,662,592 |
| Price / Earnings (TTM) | 17.00 |
| Price / Sales | 4.82 |
| Price / Book | 2.77 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2025 - 31 Mar 2025 |
| Profit Margin | 29.50% |
| Operating Margin (TTM) | -0.87% |
| Diluted EPS (TTM) | 0.220 |
| Quarterly Revenue Growth (YOY) | -42.20% |
| Quarterly Earnings Growth (YOY) | -51.30% |
| Total Debt/Equity (MRQ) | 53.89% |
| Current Ratio (MRQ) | 3.45 |
| Operating Cash Flow (TTM) | 21.08 M |
| Levered Free Cash Flow (TTM) | 7.57 M |
| Return on Assets (TTM) | 4.82% |
| Return on Equity (TTM) | 19.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | HBM HOLDINGS-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| HBM HOLDINGS-B | 3 B | - | 17.00 | 2.77 |
| GENSCRIPT BIO | 23 B | - | - | 2.42 |
| OCUMENSION-B | 3 B | - | - | 1.17 |
| TOT BIOPHARM-B | 1 B | - | 190.00 | 1.70 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
|
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 20.73% |
| % Held by Institutions | 9.97% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |